Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?

Robert S. Kern, Michael F. Green, Barringer D. Marshall, William C. Wirshing, Donna Wirshing, Susan R. McGurk, Stephen R. Marder, Jim Mintz

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the neurocognitive effects of these drugs. The present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. The study design included a baseline phase and two double-blind phases in which patients were randomly assigned to medication under two different dose conditions (fixed dose and flexible dose). Secondary memory was assessed at baseline, fixed-dose, and flexible-dose phases, using the California Verbal Learning Test (CVLT). Six measures were selected, which formed three factors (general verbal learning ability, retention, and learning strategy). Risperidone-treated patients showed greater improvement than haloperidol-treated patients in general verbal learning ability, a finding characterized by significant treatment effects on CVLT measures of learning acquisition, recall consistency, and recognition memory. After controlling for benztropine status, differences on the measures of learning acquisition and recall consistency remained significant, and differences in recognition memory weakened slightly (p = 0.07). No significant treatment effects were noted on retention or learning strategy. These findings suggest that risperidone may exert a facilitating effect on the acquisition of new verbal information, an effect that does not appear to be due to the activation of semantic encoding strategies.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalSchizophrenia Bulletin
Volume25
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Verbal Learning
Risperidone
Haloperidol
Learning
Aptitude
Schizophrenia
Benztropine
Therapeutics
Semantics
Antipsychotic Agents
Pharmaceutical Preparations
Recognition (Psychology)
Retention (Psychology)

Keywords

  • California Verbal Learning Test (CVLT)
  • Haloperidol
  • Memory
  • Risperidone
  • Verbal learning

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D., McGurk, S. R., ... Mintz, J. (1999). Risperidone versus haloperidol on secondary memory: Can newer medications aid learning? Schizophrenia Bulletin, 25(2), 223-232.

Risperidone versus haloperidol on secondary memory : Can newer medications aid learning? / Kern, Robert S.; Green, Michael F.; Marshall, Barringer D.; Wirshing, William C.; Wirshing, Donna; McGurk, Susan R.; Marder, Stephen R.; Mintz, Jim.

In: Schizophrenia Bulletin, Vol. 25, No. 2, 1999, p. 223-232.

Research output: Contribution to journalArticle

Kern, RS, Green, MF, Marshall, BD, Wirshing, WC, Wirshing, D, McGurk, SR, Marder, SR & Mintz, J 1999, 'Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?', Schizophrenia Bulletin, vol. 25, no. 2, pp. 223-232.
Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk SR et al. Risperidone versus haloperidol on secondary memory: Can newer medications aid learning? Schizophrenia Bulletin. 1999;25(2):223-232.
Kern, Robert S. ; Green, Michael F. ; Marshall, Barringer D. ; Wirshing, William C. ; Wirshing, Donna ; McGurk, Susan R. ; Marder, Stephen R. ; Mintz, Jim. / Risperidone versus haloperidol on secondary memory : Can newer medications aid learning?. In: Schizophrenia Bulletin. 1999 ; Vol. 25, No. 2. pp. 223-232.
@article{a3dba821293849a596322a065d0f2df2,
title = "Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?",
abstract = "The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the neurocognitive effects of these drugs. The present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. The study design included a baseline phase and two double-blind phases in which patients were randomly assigned to medication under two different dose conditions (fixed dose and flexible dose). Secondary memory was assessed at baseline, fixed-dose, and flexible-dose phases, using the California Verbal Learning Test (CVLT). Six measures were selected, which formed three factors (general verbal learning ability, retention, and learning strategy). Risperidone-treated patients showed greater improvement than haloperidol-treated patients in general verbal learning ability, a finding characterized by significant treatment effects on CVLT measures of learning acquisition, recall consistency, and recognition memory. After controlling for benztropine status, differences on the measures of learning acquisition and recall consistency remained significant, and differences in recognition memory weakened slightly (p = 0.07). No significant treatment effects were noted on retention or learning strategy. These findings suggest that risperidone may exert a facilitating effect on the acquisition of new verbal information, an effect that does not appear to be due to the activation of semantic encoding strategies.",
keywords = "California Verbal Learning Test (CVLT), Haloperidol, Memory, Risperidone, Verbal learning",
author = "Kern, {Robert S.} and Green, {Michael F.} and Marshall, {Barringer D.} and Wirshing, {William C.} and Donna Wirshing and McGurk, {Susan R.} and Marder, {Stephen R.} and Jim Mintz",
year = "1999",
language = "English (US)",
volume = "25",
pages = "223--232",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Risperidone versus haloperidol on secondary memory

T2 - Can newer medications aid learning?

AU - Kern, Robert S.

AU - Green, Michael F.

AU - Marshall, Barringer D.

AU - Wirshing, William C.

AU - Wirshing, Donna

AU - McGurk, Susan R.

AU - Marder, Stephen R.

AU - Mintz, Jim

PY - 1999

Y1 - 1999

N2 - The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the neurocognitive effects of these drugs. The present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. The study design included a baseline phase and two double-blind phases in which patients were randomly assigned to medication under two different dose conditions (fixed dose and flexible dose). Secondary memory was assessed at baseline, fixed-dose, and flexible-dose phases, using the California Verbal Learning Test (CVLT). Six measures were selected, which formed three factors (general verbal learning ability, retention, and learning strategy). Risperidone-treated patients showed greater improvement than haloperidol-treated patients in general verbal learning ability, a finding characterized by significant treatment effects on CVLT measures of learning acquisition, recall consistency, and recognition memory. After controlling for benztropine status, differences on the measures of learning acquisition and recall consistency remained significant, and differences in recognition memory weakened slightly (p = 0.07). No significant treatment effects were noted on retention or learning strategy. These findings suggest that risperidone may exert a facilitating effect on the acquisition of new verbal information, an effect that does not appear to be due to the activation of semantic encoding strategies.

AB - The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the neurocognitive effects of these drugs. The present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. The study design included a baseline phase and two double-blind phases in which patients were randomly assigned to medication under two different dose conditions (fixed dose and flexible dose). Secondary memory was assessed at baseline, fixed-dose, and flexible-dose phases, using the California Verbal Learning Test (CVLT). Six measures were selected, which formed three factors (general verbal learning ability, retention, and learning strategy). Risperidone-treated patients showed greater improvement than haloperidol-treated patients in general verbal learning ability, a finding characterized by significant treatment effects on CVLT measures of learning acquisition, recall consistency, and recognition memory. After controlling for benztropine status, differences on the measures of learning acquisition and recall consistency remained significant, and differences in recognition memory weakened slightly (p = 0.07). No significant treatment effects were noted on retention or learning strategy. These findings suggest that risperidone may exert a facilitating effect on the acquisition of new verbal information, an effect that does not appear to be due to the activation of semantic encoding strategies.

KW - California Verbal Learning Test (CVLT)

KW - Haloperidol

KW - Memory

KW - Risperidone

KW - Verbal learning

UR - http://www.scopus.com/inward/record.url?scp=0033017428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033017428&partnerID=8YFLogxK

M3 - Article

C2 - 10416728

AN - SCOPUS:0033017428

VL - 25

SP - 223

EP - 232

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 2

ER -